TimesSquare Capital Management LLC Buys 14,755 Shares of argenx SE (NASDAQ:ARGX)

TimesSquare Capital Management LLC boosted its position in argenx SE (NASDAQ:ARGX - Free Report) by 13.5% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 124,245 shares of the company's stock after purchasing an additional 14,755 shares during the period. argenx comprises 1.1% of TimesSquare Capital Management LLC's holdings, making the stock its 26th largest position. TimesSquare Capital Management LLC owned about 0.21% of argenx worth $76,411,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of ARGX. Global Retirement Partners LLC lifted its stake in argenx by 369.2% in the 4th quarter. Global Retirement Partners LLC now owns 61 shares of the company's stock valued at $38,000 after purchasing an additional 48 shares during the last quarter. Venturi Wealth Management LLC acquired a new stake in argenx in the 4th quarter valued at about $66,000. Nkcfo LLC acquired a new stake in argenx in the 4th quarter valued at about $68,000. Advisors Preferred LLC acquired a new stake in argenx in the 4th quarter valued at about $73,000. Finally, Cromwell Holdings LLC lifted its position in argenx by 73.3% during the third quarter. Cromwell Holdings LLC now owns 156 shares of the company's stock worth $85,000 after acquiring an additional 66 shares during the last quarter. 60.32% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have issued reports on ARGX. Piper Sandler raised their price objective on shares of argenx from $620.00 to $725.00 and gave the stock an "overweight" rating in a research report on Tuesday, January 7th. Deutsche Bank Aktiengesellschaft downgraded shares of argenx from a "hold" rating to a "sell" rating in a research report on Friday, January 17th. Scotiabank upgraded shares of argenx from a "sector perform" rating to a "sector outperform" rating and raised their price objective for the stock from $439.00 to $715.00 in a research report on Tuesday, November 5th. Truist Financial restated a "buy" rating and set a $700.00 price objective (up from $660.00) on shares of argenx in a research report on Tuesday, January 14th. Finally, Oppenheimer restated an "outperform" rating and set a $675.00 price objective (up from $646.00) on shares of argenx in a research report on Thursday, November 21st. One investment analyst has rated the stock with a sell rating, two have given a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $658.39.

argenx Price Performance

NASDAQ:ARGX traded down $3.01 during mid-day trading on Friday, reaching $644.48. The stock had a trading volume of 215,707 shares, compared to its average volume of 262,044. The stock has a 50-day simple moving average of $643.06 and a two-hundred day simple moving average of $586.56. The stock has a market capitalization of $39.16 billion, a PE ratio of -732.36 and a beta of 0.58. argenx SE has a 12 month low of $349.86 and a 12 month high of $678.21.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.